U.S. markets open in 2 hours 39 minutes
  • S&P Futures

    3,858.50
    +10.25 (+0.27%)
     
  • Dow Futures

    31,130.00
    +117.00 (+0.38%)
     
  • Nasdaq Futures

    11,915.00
    +34.75 (+0.29%)
     
  • Russell 2000 Futures

    1,735.00
    +6.40 (+0.37%)
     
  • Crude Oil

    99.31
    +0.78 (+0.79%)
     
  • Gold

    1,740.80
    +4.30 (+0.25%)
     
  • Silver

    19.33
    +0.17 (+0.89%)
     
  • EUR/USD

    1.0192
    +0.0007 (+0.07%)
     
  • 10-Yr Bond

    2.9130
    0.0000 (0.00%)
     
  • Vix

    26.65
    -0.89 (-3.23%)
     
  • GBP/USD

    1.1995
    +0.0073 (+0.62%)
     
  • USD/JPY

    135.9030
    -0.0120 (-0.01%)
     
  • BTC-USD

    20,496.27
    +380.51 (+1.89%)
     
  • CMC Crypto 200

    446.09
    +10.57 (+2.43%)
     
  • FTSE 100

    7,194.61
    +86.84 (+1.22%)
     
  • Nikkei 225

    26,490.53
    +382.88 (+1.47%)
     

Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference taking place March 28-30, 2022.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead candidate. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:
Investor Relations:
Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com